Tesla CEO Elon Musk is a visionary who thinks big, but don't trust his numbers, says Jim Cramer.
Shares of Relypsa surged on news of a takeover by Galenica, the owner of Switzerland's biggest pharmacy network.
Biogen shares could be on a turnaround trajectory after a year of disappointments.
MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.
Jim Cramer was encouraged by the slew of drug approvals Valeant Pharmaceuticals received from the FDA.
Investors are beginning to wonder if earnings season can support the latest records.
The chemicals giant grew revenues in every division and upped its bid for U.S.-based Monsanto this week.
Brainstorm's NurOwn is a personalized stem cell treatment designed to slow the progression of ALS, a fatal neurodegenerative disease.
For the week of July 18, the earnings parade continues, with dozens of major companies reporting financial results.